RxDoctor Payments Data

Brendan Guercio, MD

Internal Medicine · Rochester, NYNPI 1508247735

Payments from drug & device makers

$101,267in general payments, 2019–2025

Across 12 payments — averaging $8438.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas US Technologies$98K
  • Johnson & Johnson$1K
  • Janssen Scientific Affairs, LLC$818
  • Exelixis Inc.$390
  • Amgen$194
  • E.r. Squibb & Sons, L.L.C.$117
  • plus $171 from 2 others

What the payments were for

  • Consulting fees$2,08070%
  • Food & beverage$67823%
  • Education$1947%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,267 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$43,210
Medicare patients
108
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide50$620,026
NubeqaDarolutamide42$483,151
CabometyxCabozantinib S-Malate12$439,722
ErleadaApalutamide20$206,272
LynparzaOlaparib16$172,381
OrgovyxRelugolix53$140,946
Abiraterone Acetate21$50,700
Bicalutamide40$1,122
Prochlorperazine Maleate66$779
Dexamethasone32$507
Finasteride21$220
Gabapentin21$188
Ondansetron Hcl35$175
Oxycodone Hcl17$156
Triamcinolone Acetonide11$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$390$439,72212 claims
Johnson & JohnsonErleada$1,263$206,27220 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$818$50,70021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →